Anthony Adam Rosenberg

Anthony Adam Rosenberg currently works at TR Advisory Services GmbH, as Chief Executive Officer from 2015, Oculis SA, as Chairman from 2018, Cullinan Therapeutics, Inc., as Chairman from 2020, Oculis Holding AG, as Chairman from 2023, Cullinan Mica Corp., as Director, argenx SE, as Independent Non-Executive Director from 2017, SiO2 Medical Products, Inc., as Director, Nuclidium AG, as Director, and Kurma Partners SA, as Senior Advisor from 2022.
Mr. Rosenberg also formerly worked at Idenix Pharmaceuticals LLC, as Director from 2009 to 2012, Idenix Pharmaceuticals LLC, as Director from 2012 to 2013, Genoptix, Inc., as Director, Radius Health, Inc., as Independent Director from 2015 to 2020, Clinical Ink, Inc., as Director, MPM BioImpact LLC, as Managing Director from 2015 to 2020, TriNetX, LLC, as Director, Cullinan Oncology LLC, as Independent Director from 2017 to 2020, European Biotech Acquisition Corp., as Director, Clinincal Ink, Inc., as Director, iOmx Therapeutics AG, as Member-Supervisory Board, Novartis International AG, as Head-Mergers, Acquisitions & Licensing from 2012 to 2015, and Novartis Pharmaceuticals Corp., as Global Head-Business Development & Licensing from 2005 to 2012.
Mr. Rosenberg received his graduate degree from the University of London and undergraduate degree from the University of Leicester.